Preparation of a dual cored hepatoma-specific star glycopolymer nanogel via arm-first ATRP approach shaofeng lou 
Introduction
Extensive efforts have been made in nanomedicine development in order to improve drug loading efficiency and controlled drug release in response to environmental stimuli with reduced systemic toxicity. 1, 2 In the past decade, research within the fields of nanomedicine has demonstrated that nanodrug delivery systems could substantially improve drug bioavailability and local concentration by preventing premature degradation, controlled release, and enhanced permeability and retention effect. 3, 4 However, rapid systemic elimination and unspecific and burst release are still major concerns that limit clinical potential of nanomedicine. To optimize nanodrug delivery system, design, and development of multivalent nanoparticles by surface conjugation of bioactive targeting moieties, stimuliresponsive monomers and anti-adsorptive copolymer blocks have been reported.
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Star polymer nanogels, also termed smart drug delivery systems, have shown potential as efficient diagnostic and/or therapeutic tools against cancer, infectious diseases, or neurodegenerative disorders. [11] [12] [13] Indeed, it has been reported that star-shaped polymer nanogels prepared by controlled/"living" radical polymerization are, in principle, suitable for delivery of multi-functional molecular cargos (eg, drugs, gene, and imaging agents), controlling cellular uptake, and triggering intracellular release. 14 In addition, star polymer nanogels also exhibit stable physicochemical properties, which are responsible for their prolonged systemic retention. 15 Moreover, star polymer nanogels are often composed of a hydrophobic core formed by polymer cross-linkage and hydrophilic "arms". This unique architecture enables high drug loading capacity due to hydrophobic interaction between drugs and the core, and the "arms" allow extensive modifications with chemical and bioactive ligands for active and targeted delivery. A wide range of bioactive ligands including proteins and their bioactive fragments, short-chain peptides, nucleic acid aptamers, folic acid, and sugar molecules have been selected for nanogel modifications. 5 Glycosylation is one of the promising approaches for active targeted delivery due to the inherent biocompatibility and bioadhesiveness of sugar molecules and the pivotal roles of carbohydrate recognition mechanisms in major biological events. 16 Studies have reported functionalization with terminal fructopyranose moieties for breast cancer cells targeting, 17 and mannose as specific ligand for immune scavenge cells such as macrophages and dendritic cells. 18, 19 Moreover, glycosylated nanocarriers with terminal galactose or lactose moieties have also shown selectivity for hepatic cells, with clinical relevance for hepatoma chemotherapy or hepatitis C treatment. 20 Indeed, hepatoma, the most common type of human cancer, is known to express abnormally high level of the asialoglycoprotein receptors (ASGP-Rs) that are responsive to carbohydrate motifs including the N-acetyl galactosamine, galactose, and lactose. 4, 6, 10, [21] [22] [23] [24] [25] It is also noteworthy that malignant tumor cells also elicit changes in the stroma for rapid growth and progression, thus creating an abnormal microenvironment characterized by hypoxia, acidity, and overexpression of surface receptors and enzymes. 1, 4, 9 Given the distinct tumor microenvironment, designing polymeric micelles that are responsive to redox reaction, pH, and temperature changes to facilitate tumor-specific drug release has been an effective tumor-targeted drug delivery approach. In particular, the utilization of disulfide-containing reversible cross-linkers has gained ample research attention, owing to the fact that the disulfide bond is reducible and can be cleaved by reductase such as glutathione (GSH), an endogenous anti-oxidant that could translocate to the cell surface. 24, 26 Considering the targeting ability of glycosylation and the unique characteristics of tumor microenvironment, a reductase-cleavable and thermo-responsive star-shaped polymer nanogel was prepared via an "arm-first" atom transfer radical polymerization (ATRP) approach for targeted hepatoma drug delivery (Scheme 1). The thermo-and redox-sensitive core is composed of disulfide bonds (-S-S-) cross-linked poly(N-isopropylacrylamide) (PNIPAM), which is conjugated with arms formed of anti-adsorptive zwitterionic copolymer block and poly(sulfobetaine methacrylate) (PSBMA), to minimize interactions of the polymeric nanogels with plasma protein and cells. A lactose moiety, poly(2-lactobionamidoethyl methacrylamide) (PLAMA), was also included as targeting segment that recognizes hepatocellular ASGP-Rs. Characteristics of the star-shaped nanogels were assessed by nuclear magnetic resonance (NMR) and transmission electron microscope (TEM). Drug releasing property in response to thermo and redox changes was assessed using DOX as a model anti-cancer drug. Cytotoxicity, drug uptake, and intracellular releasing kinetics of the DOX-loaded nanogels were evaluated in human hepatocellular cancer cells (HepG2) and non-hepatic cervical cancer cells (HeLa) as control.
Material and methods chemicals
Doxorubicin hydrochloride (DOX⋅HCl) was purchased from Beijing Huafeng United Technology Co., Ltd. Lactobionic acid, 2-aminoethyl methacrylate hydrochloride, and N,N′-bis(acryloyl)cystamine (BAC) were purchased from Sigma-Aldrich. N-isopropylacrylamide (NIPAM; Sinopharm Chemical Reagent Co., Ltd) was recrystallized from an n-hexane/toluene mixture. CuBr (Tianjin, People's Republic of China, analytical reagent) was purified by dissolving in concentrated HCl, precipitating in water, washing with ethanol and ethyl ether three times, and then drying under vacuum. The following reagents were of analytic grade and used as received: 2-bromoisobutyryl bromide (Tokyo Chemical Industry), dithiothreitol (Acros Organics), 2,2′-bipyridine (bpy 99%, Sigma-Aldrich), and triethylamine (Sigma-Aldrich). 2-Lactobionamidoethyl methacrylamide (LAMA) was synthesized using a method described elsewhere. 27, 28 Water was purified by a Milli-Q system (Millipore Corporation) to a specific resistivity of ~18 MΩ cm. All solvents were distilled and dried by storing over activated 4Å molecular sieves for 24 h prior to use. synthesis of laMa LAMA was synthesized as reported before. 27, 28 Briefly, lactobionic acid was dissolved in anhydrous methanol at 50°C with aliquot trifluoroacetic acid as catalyst, followed by Figure 1 . The white solid formed was filtered, washed with 2-propanol, dried under vacuum, and isolated in 72% yield.
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synthesis of PlaMa macroinitiator
PLAMA macroinitiator (PLAMA-Br) was prepared by ATRP with CuBr complexed by bpy as the catalyst in DMF at 60°C. Copper(I) bromide (0.012 g, 0.085 mmol) and two equiv of bpy (0.026 g, 0.170 mmol) were first dissolved in dry DMF (5 mL) in a 10 mL two-neck flask and degassed with two freeze-pump-thaw cycles. 2-Bromoisobutyryl bromide (0.028 g, 0.142 mmol, target DP n =30) and LAMA (2.0 g, 4.26 mmol) were dissolved in dry DMF (3.5 mL) in a 10 mL two-neck flask and degassed with two freeze-pumpthaw cycles. Then the solution was added into the solution through a syringe under nitrogen atmosphere, and the mixture was degassed with another three freeze-pump-thaw cycles. The reaction mixture was then stirred at 60°C for 12 h. The resulting dispersions were dialyzed (cutoff 3,500 Da) against water for 48 h to ensure complete removal of unreacted monomers and recovered by lyophilization.
synthesis of zwitterionic diblock glycopolymer PlaMa-b-PsBMa-Br with PlaMa macroinitiator
Copper(I) bromide (0.021 g, 0.147 mmol) and two equiv of bpy (0.045 g, 0.294 mmol) were first dissolved in dry DMF (5 mL) in a 10 mL two-neck flask and degassed with two freeze-pump-thaw cycles. PLAMA-Br (1.3 g, 0.098 mmol) and SBMA (0.55 g, 1.97 mmol) were dissolved in DMF and Milli-Q water mixture (3:5) in a 10 mL two-neck flask and degassed with two freeze-pump-thaw cycles. Then the solution was added into the solution through a syringe under nitrogen atmosphere, and the mixture was degassed with another three freeze-pump-thaw cycles. The reaction mixture was then stirred at 60°C for 12 h. The resulting dispersions were dialyzed (cutoff 8,000 Da) against water for 48 h to ensure complete removal of unreacted monomers and recovered by lyophilization.
Preparation of zwitterionic triblock star-shaped glycopolymer s-(PlaMa-bPsBMa)-b-PNIPaM nanogels
Copper(I) bromide (0.021 g, 0.147 mmol) and two equiv of bpy (0.045 g, 0.294 mmol) were first dissolved in dry DMF (5 mL) in a 10 mL two-neck flask and degassed with two freeze-pump-thaw cycles. PLAMA-b-PSBMA-Br (1.6 g, 0.098 mmol), BAC (0.5%-2% molar ratio), NIPAM (0.331 g, 2.99 mmol), and Span 80 (0.10 g) were dissolved in DMF and water mixture (2:5) in a 10 mL two-neck flask and degassed with two freeze-pump-thaw cycles. Then the solution was added into the solution through a syringe under nitrogen atmosphere, and the mixture was degassed with another three freeze-pump-thaw cycles. The reaction mixture was then stirred at 50°C for 12 h. The resulting dispersions were dialyzed (cutoff 8,000 Da) against water for 48 h to ensure complete removal of unreacted monomers and recovered by lyophilization. The temperature was increased from 10°C to 45°C at 1°C/5 min, and absorption recorded at each temperature. The upper critical solution temperature (UCST) or lower critical solution temperature (LCST) in a particular solution condition was the midpoint of the temperature absorption curve. 29, 30 The average hydrodynamic diameter of the s-(PLAMA-b-PSBMA)-b-PNIPAM in water was measured by dynamic light scattering (DLS) (Brookhaven BI-200SM goniometer) equipped with a solid state laser source emitting at 532 nm and fitted with an external water bath and thermostat. The volume phase transition temperatures of the nanogels were examined by microcalorimetric analyses.
For encapsulation of DOX into the nanogels, dried nanogels (10.0 mg) were allowed to stir in water (20 mL) for 2 days to become fully swollen and then mixed with DOX (2.0 mg). The resulting reddish mixture was stirred for 24 h, and then transferred to a dialysis tube (M W =3,400 kDa) in aqueous. 
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Dual cored hepatoma-specific star glycopolymer nanogel microgels before and after adding 10 mM with an intracellular level within millimolar range (1-10 mM) and extracellular concentration typically at micromolar (20-40 µM) level was measured by TEM (JEOL, JSM-7500F) for 4 h.
In vitro drug release assay
In vitro drug release experiments were performed as following: 10 mg of freeze-dried DOX-loaded nanogels with 2 mL phosphate-buffered saline (PBS) buffer was placed into a dialysis bag (MWCO 3500). Then the release system was suspended in 10 mL of different temperature and aliquot GSH in PBS solution. After a predetermined period, 2 mL of solution was taken from release system for analysis, and 2 mL of fresh medium was added into the release buffer. The DOX concentration of each aliquot was determined by UV-vis analysis at 480 nm. All release experiments were carried out in triplicate. The release percentage of DOX was calculated using Eq (1):
where M t is the amount of DOX released from the nanogels at time t and M ∞ is the amount of the DOX loaded in the nanogels.
In vitro cytotoxicity assay
Cytotoxicity of DOX-s-(PLAMA-b-PSBMA)-b-PNIPAM was assessed using a cell counting kit-8 (CCK-8). The human hepatoma HepG2 and cervical carcinoma HeLa cell lines were purchased from Type Culture Collection of the Chinese Academy of Sciences, Shanghai, People's Republic of China. Briefly, human hepatoma HepG2 and cervical carcinoma HeLa cells were maintained in high-glucose Dulbecco's Modified Eagle's Medium (Hyclone) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin under standard cell culture condition (37°C, 5% CO 2 /95% air). For both HepG2 and HeLa, the cells were seeded at a density of ~5-6×10 However, the size of the nanogels detected by TEM was smaller than that determined by DLS (Table 2) , likely due to shrinkage of nanoparticles during the drying process required prior to TEM. By contrast, in the presence of 10 mM GSH, the nanogels fused and the average size decreased from ~120 to ~70 nm ( Figure 2C ), as a result of GSH-induced disulfide bond breakage and polymer backbone dissolving. This rapid GSH-triggered nanogel disintegration enables specific drug release in tumor cells where reducing environment with high GSH concentration is characterized.
Phase transition temperatures of s-(PlaMa-b-PsBMa)-b-PNIPaM nanogels in aqueous solution
PolyNIPAM is the most widely studied thermo-responsive polymer that undergoes sharp phase transition at a LCST of 32°C. By contrast, polySBMA, one example of zwitterionic polymers, exhibits an UCST in aqueous solution between 16°C and 18°C, which indicates that the homopolymers in a dilute aqueous solution elicit a dramatic change in absorbance. 29 It has been reported previously that solubility of a similarly conjugated thermo-responsive copolymer occurs between the LCST and UCST values of the two polymer segments, as a result of intermolecular and intramolecular electrostatic interactions within the zwitterionic 
3659
Dual cored hepatoma-specific star glycopolymer nanogel sulfobetaine groups of the SBMA segments, as well as the intramolecular hydrophobic interactions of nonionic isopropyl groups within the NIPAM segments. 30 Consistent with previous reports, at temperatures below the UCST of PSBMA, s-(PLAMA-b-PSBMA)-b-PNIPAM nanogels exist as a collapsed coil and precipitate in water due to strong electrostatic of the zwitterionic groups. At temperatures above the LCST of PNIPAM, the PNIPAM chains become more hydrophobic and the hydrogen bonds formed with water molecules weaken, resulting in collapse of the polyNIPAM coils and polymer conjugation. As shown in Figure 3 , the s-(PLAMA-b-PSBMA)-b-PNIPAM nanogels are soluble over a temperature range of 20°C-35°C (low absorbance), and the increase of absorbance was observed at temperatures either higher than 35°C or lower than 20°C. The LCST of the PNIPAM-PSBMA copolymer increased because both PLAMA and PSBMA block are hydrophilic polymers. In addition, phase transition of s-(PLAMA-b-PSBMA)-b-PNI-PAM nanogels in aqueous solution was studied as a function of temperature to investigate the effect of varied cross-linker ratios of copolymers on both UCST and LCST. Data in Table 2 show an inverse correlation between cross-linker ratio and UCST values from 18.6°C to 16.9°C. By contrast, increase in cross-linker ratio correlates to increased LCST values from 39.1°C to 36.5°C, suggesting that the increase of PNIPAM block cross-linking contributes to the insoluble collapsed coil state of the PNIPAM-PSBMA copolymers.
Drug loading and releasing property of star polymer nanogel
Drug release behaviors of s-(PLAMA-b-PSBMA)-b-PNIPAM nanogels in response to different stimuli were investigated and the results are shown in Figure 4 . The LC of nanogels (BAC 0.5%) was lower than that of nanogels (BAC 1.0%) and nanogels (BAC 2.0%), indicating that the hydrophobic cross-linking chain plays an important role in this process. The temperature sensitive nanogels remain soluble as the temperature is below its LCST and after the nanogels start circulating to the malignant hyperthermal tissue, the nanogels precipitate, and the drug is released. Given such sensitivity to temperature changes, these nanogels would be employed for local tumor hyperthermia therapy. Among these incubation conditions, 37°C and 40°C represent the normal physiological temperature and hyperthermia treatment temperature, respectively. To investigate the influence of temperature changes on drug release, the experiments were conducted in buffer solutions at pH 6.5 (to mimic the physiological pH of endosome) at different temperatures. It was observed that the UcsT and lcsT were determined by reading the absorbance at 550 nm on a UV-visible spectrophotometer.
c,d
average diameter of nanogels and polydispersity index were determined by a Zetasizer Nano Zs instrument at 25°C. The EE and drug LC are defined as follows: lc % Weight of DOX in nanogels Weight of nanogels ( ) ( / ) = × 100% ee % Weight of DOX in nanogels Weight of DOX in feed ( ) ( / ) = × 10 00%. Abbreviations: Bac, N,N′-bis(acryloyl)cystamine; lcsT, lower critical solution temperature; UcsT, upper critical solution temperature; PlaMa, poly(2-lactobionamidoethyl methacrylamide); PSBMA, poly(sulfobetaine methacrylate); PNIPAM, poly(N-isopropylacrylamide); EE, entrapment efficiency; LC, loading capacity; DOX, doxorubicin.
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lou et al DOX release rate increased as the temperature decreased from 40°C to 37°C and 30°C. Drug release in response to environmental redox changes was also investigated in parallel to assess whether the lactose-functionalized nanogel could be degraded by GSH. The release rate of DOX was significantly enhanced in the presence of 10 mM GSH regardless of environmental temperature conditions, showing a maximum of 80% drug release within 24 h. The accelerated drug release from the redox-degradable nanogels, to some extent, demonstrates that the rate of drug release was dependent on the cleavage rate of disulfide bond within the PNIPAM core. To further elucidate the in vitro thermo-responsive drug release mechanism of DOX-nanogels, we chose (0 mM GSH, 37°C) release profile as an example; the data were analyzed using the zero-order equation, Higuchi equation, and Ritger-Peppas equation models. The fitting results are (zero exponential: Q =0.012*t +0.139, r 2 =0.926; RitgerPeppas) lnQ =1.815*lnt +4.425, r 2 =0.95896; Higuchi: Q =2.65*t1/2+7.277, r 2 =0.8415. For in vitro GSH-responsive drug release mechanism of DOX-nanogels, we chose (10 mM GSH, 37°C) release profile as an example; the data were analyzed using the zero-order equation, Higuchi equation, and Ritger-Peppas equation models (zero exponential: Q =2.041*t+22.083, r 2 =0.9016; RitgerPeppas: lnQ =0.542*lnt-1.952, r 2 =0.9237; Higuchi: Q =0.148*t1/2+0.031, r 2 =0.9863). These results revealed that the in vitro release profile of DOX-nanogels with GSH followed the Higuchi equation (r 2 =0.9863). These indicate that DOX release was the synergistic effect of nanogel degradation and drug diffusion. 31, 32 The dual-sensitivity-triggered DOX release behavior could be explained by the coordinated dual sensitivity.
assessment of hepatic targeting property and anti-tumor activity
To evaluate the hepatic targeting ability of the nanogelbased delivery system and its cytotoxicity, human hepatoma HepG2 cells were used since the lactose groups are known to recognize the ASGP-R, a recycling endocytotic receptor often found overexpressed by HepG2. Human cervical carcinoma cells, HeLa, that do not express ASGP-R were used as negative control. The blank nanogel s-(PLAMA-b-PSBMA)-b-PNIPAM showed very low cytotoxicity even at fairly high concentrations up to 10 mg/mL ( Figure 5 ). The cytotoxicity of DOX and DOX-loaded s-(PLAMA-b-PSBMA)-b-PNIPAM was measured by CCK-8 assay. HeLa and HepG2 cells were treated with free DOX or DOX-loaded nanogels at a series of DOX concentrations ranging from 0.001 to 10.0 µg/mL for 24 and 48 h. As shown in Figure 6 , the lactosylated nanogel exhibited lower activity in inhibiting proliferation of HepG2 cells in the presence of galactose because the presence of galactose would mask the lactosylated segment on the nanogel and disrupt the hepatomatargeting ability of the nanogel. 6 By contrast, addition of galactose only affected the proliferation activity of HeLa cells moderately, confirming that the hepatoma-targeting property of the lactose-bearing nanogel was dependent 
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Dual cored hepatoma-specific star glycopolymer nanogel on ASGP-R recognition by the lactosylated moiety. As expected, the presence or absence of galactose did not affect the inhibiting activity of free DOX for HepG2 and HeLa cells.
Indeed, DOX-loaded nanogels exhibited higher inhibitory effect on the proliferation of HepG2 cells that express ASGP-R compared to HeLa cells. Remarkably, the presence and absence of galactose dramatically affected the IC 50 values of DOX-loaded nanogels ( Table 3 . Changes in IC 50 values by addition of galactose in HepG2 cells indicate ASGP-R-specific binding of the lactosylated segment. It is noteworthy that the IC 50 of lactosylated nanogels was close to that of free DOX (0.21 µg/mL), suggesting excellent drug release and liver-specific targeting. Furthermore, the hepatic-specific targeting property of the lactosylated nanogels was confirmed by results obtained from HeLa cells. The cytotoxicity (Figure 7 ), whereas no difference was detectable in HeLa cells regardless of galactose (Figure 7) , highlighting the facilitative role of lactose moiety on hepatoma targeting. Flow cytometry was also employed to investigate the effect and mechanisms of DOX-s-(PLAMA-b-PSBMA)-b-PNIPAM nanogels on intracellular DOX uptake. Consistent with CLSM data, the results indicate that addition of 
Conclusion
In the present study, we prepared thermo-and redox-sensitive star-shaped nanogels. The star-shaped nanogels consist of a thermo-and redox-sensitive core that is composed of disulfide cross-linked PNIPAM, and "arm" segments of zwitterionic PSBMA and PLAMA. In vitro DOX release from nanogels was accelerated in conditions that mimic malignant cell microenvironment characterized as hyperthermal with high GSH concentration. Our results also demonstrate that the (PLAMA-b-PSBMA)-b-PNIPAM nanogels enhanced and selected DOX delivery in HepG2 cells as the result of lactose residue-specific binding with the ASGP-R (Scheme 2). In summary, our data indicate that the lactose-functionalized multi-responsive nanogels could be potentially used for drug delivery against hepatic cancers.
